What is the market's earnings forecast for Abbott Laboratories next quarter?

What is Abbott Laboratories's gross profit margin?

What were the key takeaways from Abbott Laboratories’s earnings call?

What does Abbott Laboratories do and what are its main business segments?

What were the key takeaways from Abbott Laboratories's earnings call?

What is the revenue and EPS growth rate for Abbott Laboratories year over year?

What is Abbott Laboratories's latest dividend and current dividend yield?

What guidance did Abbott Laboratories's management provide for the next earnings period?

- **Organic Growth Momentum**: 7.5% organic sales growth driven by Medical Devices (12.5%) and Established Pharmaceuticals (7%).
- **Star Performers**: CGM sales hit $2B (+17%), EP ablation catheters grow double-digit, and TriClip launched in Japan.
- **2026 Confidence**: CEO reaffirms 7.5% sales and 10% EPS growth targets, citing new products and headwind resolution.
- **Tariff Mitigation**: Gross margin pressure from tariffs, but cost control efforts limit impact.
- **China Recovery**: Diagnostics headwinds expected to ease in 2026, with international growth compensating for China volume declines.

**【CEO Summary Section】**
- **Organic Sales Growth**: 7.5% excluding COVID tests, driven by double-digit growth in Medical Devices (12.5%) and high single-digit growth in Established Pharmaceuticals (7%).
- **Key Product Performances**: 
  - Diabetes Care: Continuous glucose monitor (CGM) sales reached $2B, up 17%.
  - Electrophysiology (EP): Ablation catheters grew double-digit in the U.S. and internationally, with Volt PFA catheter launch in Europe successful.
  - Structural Heart: 11% growth led by TAVR share gains and TriClip adoption in Japan.
- **New Product Contributions**: Recently launched products added $0.5B in sales, with 100+ basis points to organic growth. 2026 outlook includes launches of Volt in the U.S., TactiFlex Duo, and biosimilars.
- **Challenges**: Tariffs impacted gross margin, but cost control measures mitigated部分影响.

**【CFO Financial Commentary】**
- **Adjusted EPS**: $1.30, in line with consensus, reflecting 7.5% organic sales growth and 40 basis points improvement in operating margin.
- **Gross Margin**: 55.8% of sales, down due to tariffs, but tariff mitigation efforts expected to reduce impact in 2026.
- **R&D and SG&A**: 6.4% and 26.4% of sales, respectively, supporting innovation and commercial execution.
- **FX Impact**: 1.4% favorable year-over-year, expected to remain similar in Q4.

**【Q&A Key Highlights】**
- **2026 Outlook**: CEO confident in delivering 7.5% organic sales growth and 10% EPS growth, citing underlying momentum, new product launches, and easing headwinds in Diagnostics.
- **Diabetes Growth**: U.S. CGM growth at 25% YTD, with dual-analyte sensor launch in 2026 targeting intensive insulin users. CMS coverage for non-insulin type 2 diabetes expected in 2026.
- **EP Franchise**: Double-digit growth in 2025, with Volt PFA catheter U.S. launch in mid-2026. EP pipeline includes balloon TAVR and mitral valve replacement trials.
- **China Dynamics**: Diagnostics headwinds from VBP and DRG updates expected to ease in 2026, with international growth offsetting China volume declines.
- **Sustainability of Device Growth**: CRM and Vascular businesses transitioning to mid-single-digit growth, supporting overall Medical Devices double-digit growth.


Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 7.5% Q2 and 8% H1 (ex-COVID), driven by Medical Devices (12%), EPD (8%), and Nutrition (3.5%).
- **Margin Expansion**: 100bps gross and operating margin improvement, adjusted EPS up 11% YoY to $1.26.
- **Key Products**: Libre Diabetes Care (+19.5%), Volt PFA catheter launched internationally, Tendyne mitral valve approved.
- **Strategic Initiatives**: Dual-analyte sensor in development, biosimilar pipeline for 2026 launches, CRM portfolio expansion.
- **Challenges**: $1B headwinds from COVID testing and China Diagnostics, $200M tariff impact.
- **Guidance**: High single-digit sales growth, double-digit EPS growth for FY25, with FY26 outlook positive post-headwinds.

**【CEO Summary Section】**
- **Overall Performance**: Delivered 7.5% organic sales growth in Q2 and 8% in H1, excluding COVID testing. Adjusted EPS of $1.26 exceeded expectations, up 11% YoY. Margin expansion of 100 basis points in gross and operating margins.
- **Business Highlights**:
  - **Nutrition**: 3.5% Q2 growth, driven by Adult Nutrition (6.5% growth) with strong demand for Ensure and Glucerna.
  - **Diagnostics**: 1.5% decline due to $700M COVID testing headwind and China volume procurement programs. Core Lab outside China grew 8%.
  - **EPD**: 8% growth, with key 15 markets surpassing $1B quarterly sales. Biosimilar pipeline includes 10 regulatory submissions for 2026 launches.
  - **Medical Devices**: 12% growth, led by Diabetes Care (19.5%), EP (double-digit growth), and Structural Heart (12% growth). New products like Volt PFA catheter and Tendyne mitral valve approved.
- **Strategic Initiatives**: Collaboration with Epic for Libre glucose monitor integration. Dual-analyte sensor in development for ketone monitoring. Expansion of CRM portfolio with AVEIR leadless pacemaker.

**【CFO Financial Commentary】**
- **Financials**: Q2 sales $11.1B (6.9% growth), adjusted EPS $1.26 (+11% YoY). Gross margin 57% (+100bps YoY). R&D/S&A at 6.3%/27.7% of sales. Operating margin 22.9% (+100bps YoY).
- **FX and Tariffs**: FX neutral for FY25, with $200M tariff impact. Q3 EPS guidance $1.28-$1.32.
- **Outlook**: High single-digit sales growth, double-digit EPS growth, despite $1B headwinds from COVID testing and China Diagnostics.

**【Q&A Key Highlights】**
- **Diagnostics Headwinds**: China Core Lab recovery delayed to Q4. $1B headwinds from COVID testing and U.S. HIV funding. Non-China Core Lab growth strong (U.S. +7%, Europe +8%).
- **EP Growth**: Volt PFA catheter launched internationally with best-in-class paroxysmal AF data. CRM portfolio expansion with AVEIR (10% Q2 growth, 50% trained physician increase).
- **Diabetes Innovation**: Dual-analyte sensor in development for ketone monitoring. Libre U.S. growth 26%, commercial coverage doubling over 3 years.
- **M&A Strategy**: Focused on diagnostics and MedTech, seeking strategic fits with attractive ROIC. No immediate large deals, but active pipeline.
- **Biosimilars**: Launching in small markets Q4, scaling in 2026. Leverage existing infrastructure in emerging markets for women's health, autoimmune, and oncology products.


Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript

- **Q1 Growth Strong**: 7% revenue growth (8.3% ex-COVID), EPS +11% vs. prior year.
- **Key Drivers**: CGM up 20%, Vascular Imaging double-digit, biosimilars pipeline expanded.
- **Tariff Mitigation**: $0.5B annual impact, but 90-site manufacturing network provides long-term solutions.
- **Pipeline Power**: 25+ new products launching over 3 years, includingVolt PFA and IVL trial.
- **Margins Expand**: Gross margin +140bps, operating margin +130bps YoY.


**【CEO Opening Remarks】**
- **Q1 2025 Performance**: Revenue grew 7% (8.3% excluding COVID testing), adjusted EPS of $1.09 (+11% YoY), meeting high end of guidance.
- **Business Highlights**: 
  - **Nutrition**: 7% growth driven by Adult (+8.5%) and Pediatric (+double-digit) Nutrition.
  - **Medical Devices**: 12.5% growth, with CGM up 20% (US +30%), and Vascular Imaging double-digit growth.
  - **EPD**: 8% growth, biosimilars pipeline expanded to 15 products.
  - **Structural Heart**: 15% growth, TriClip adoption driven by 2-year clinical data showing reduced heart failure hospitalizations.
- **Pipeline Momentum**: 25+ new products expected to launch over next 3 years, includingVolt PFA (Europe CE Mark), IVL coronary lithotripsy trial, and nucleic acid blood screening system.
- **Tariff Mitigation**: $0.5B annual impact expected, with long-term solutions via global manufacturing network (90 sites) and CapEx investments.

**【CFO Financial Update】**
- **Q1 Financials**: 
  - GAAP net income: $420M; Non-GAAP EPS: $1.09 (+11% YoY).
  - Gross margin: 57.1% (+140bps YoY), operating margin: 21% (+130bps YoY).
  - FX impact: 2.8% YoY headwind, but Q1 saw favorable rate movement.
- **2025 Outlook**: 
  - Full-year EPS guidance reaffirmed, despite tariff headwinds.
  - Q2 EPS guidance: $1.23-$1.27.

**【Q&A Key Themes】**
1. **Tariff Impact**: 
   - Estimated $0.5B annual impact, with 2025 impact concentrated in H2.
   - Mitigation strategies: inventory build, manufacturing network optimization, FX hedging.
2. **EPD Growth**: 
   - VOLT PFA Europe rollout underway, US approval expected early 2026.
   - Biosimilar pipeline to contribute $0.5B+ annually by 2027.
3. **Diagnostics Challenges**: 
   - China VBP causing 5%+ margin pressure, but US/EMEA core lab growth 7-8%.
   - $1B+ nucleic acid blood screening system launch planned for 2025.
4. **Rhythm Management**: 
   - AVEIR leadless pacemaker accounts +50%, implants +30% YoY.
   - Next-gen AVEIR with 25% longer battery life in development.


Abbott Laboratories (ABT)-16 Apr 25-2025 Q1 Earnings call transcript

- **2024 Strong Finish**: 10% Q4 organic growth, 13% EPS growth, capping 9.5% annual growth (ex-COVID).
- **2025 Guidance**: 7.5-8.5% sales growth, 11% EPS growth, 80bp gross margin expansion.
- **CGM Dominance**: $6.5B annual sales (+22%), 27% US market share gain; Lingo OTC launch shows promise.
- **Structural Heart Surge**: 23% growth driven by TriClip, Navitor, and Amulet; pipeline innovations on track.
- **Tax & FX Management**: 17% tax rate, 2.5% FX headwind; $8.5B+ free cash flow for shareholder returns.

**【CEO Opening Remarks】**
- Q4 2024 organic sales grew 10%, with adjusted EPS up 13% YoY, capping a year of 9.5% organic growth (ex-COVID) and 70bp gross margin improvement.
- 2025 guidance: 7.5-8.5% organic sales growth, $5.05-5.25 EPS (midpoint +11%).
- Key drivers: CGM ($6.5B/yr, +22%), Structural Heart (+23%), EPD (+8.5%), and Nutrition (+7%).
- 2025 targets: 80bp gross margin expansion, $8.5B+ operating cash flow, $5B+ shareholder returns.

**【CFO Financial Update】**
- Q4 GAAP net income: $1.3B; Non-GAAP EPS: $1.08 (vs. $1.03 est.).
- 2025 forecast: 57% gross margin, 23.5-24% operating margin, 16-17% tax rate.
- FX headwinds: ~2.5% FY25, 3.5% Q1.
- Free cash flow: ~$8.5B, supporting debt repayment and buybacks.

**【Q&A Highlights】**
- **CGM Supply & Lingo Launch**: Libre 3 supply stabilized; Lingo OTC launch shows strong reorder rates, targeting US expansion.
- **EPD Growth**: 8.5% Q4 growth driven by balanced portfolio; 2025 outlook for high single digits despite PFA competition.
- **Structural Heart**: 23% growth led by TriClip, Navitor, and Amulet; pipeline includes dual-energy catheter trials.
- **MedTech Market Health**: Utilization growth (+12% MedTech sales) driven by innovation, stable pricing, and demographic trends.
- **Tax Policy**: 2025 tax rate up to 17% due to Pillar 2; $200M incremental tax impact, mostly outside US.
- **M&A Strategy**: Selective, return-focused; pipeline strength allows disciplined capital allocation.

ABT

ABT fundamentals

Earnings Call

You can ask Aime